|
| Exchange Received Time 13/11/2017 17:28:56 Exchange Disseminated Time 13/11/2017 17:29:06 Time Taken 00:00:10 | The Board of Directors in its meeting held on 13 November 2017 had approved the following:
1.Un-audited Financial Results for the quarter and half year ended 30 September 2017.
2.To enhance the manufacturing capacity of Ibuprofen and enhance the capacities of backward integrated products with a project cost of Rs 200 crore which will be met through combination of equity, internal accruals and loans over a period of two years.
3.Setting up Unit IV for manufacturing Metformin an anti diabetic drug with project cost of Rs 10 crore which will be financed through internal accruals.
Further the Company has completed and commercialized Unit III to manufacture Fenofibrate, Clopidogrel and Lamotrigine etc. with project cost of Rs 16.48 crore met through internal accruals.
Kindly note that the meeting of Board of Directors commenced at 12:00 noon and concluded at 04:50 p.m.
Outcome of the Board meeting in attached herewith for your information. |
|
|